Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice

被引:52
作者
Wu, Duo-Jiao [1 ]
Xu, Jian-Zhong [1 ]
Wu, Yong-Jie [1 ]
Jean-Charles, Lafarge [2 ]
Xiao, Bing [1 ]
Gao, Ping-Jin [1 ,3 ]
Zhu, Ding-Liang [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Key Lab Vasc Biol, Shanghai Inst Hypertens,Dept Cellular & Mol Biol, Key Lab Med Genom,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China
[2] Sino French Res Ctr Life Sci & Genom, Shanghai, Peoples R China
[3] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci Ctr, Lab Vasc Biol, Shanghai, Peoples R China
关键词
Fasudil; Atherosclerosis; Plaque; Micro-ultrasound; Mice; RHO-KINASE; ULTRASOUND; PRAVASTATIN; INHIBITOR; SYSTEM; ARTERY; WALL;
D O I
10.1016/j.atherosclerosis.2009.04.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rho kinases have been shown to be involved in the pathogenesis of atherosclerosis. This study examined the effects of fasudil, a specific Rho kinase inhibitor, on plaque development and progression in atherosclerotic mice. Sixty apolipoprotein E-knockout (apoE-KO) mice were fed a high-fat diet. Mice started to receive fasudil at the same time as fat feeding (early treatment), or after 12 weeks of fat feeding (delayed treatment). In each administrative schedule, mice were divided into three groups: low dose fasudil group (30 mg/kg/day), high dose fasudil group (100 mg/kg/day) and control group (tap water) (n = 10, respectively). Plaque size was determined by using ultrasound biomicroscopy (UBM) and histological examinations. Brachiocephalic artery UBM analysis showed that in early treatment, both doses of fasudil significantly reduced lesion size compared with the controls (P < 0.05). In delayed-fasudil treatment, plaque area was reduced by 54% (P < 0.05) after 12 weeks of treatment at a high dose of fasudil (100 mg/kg/day). The UBM findings were confirmed by histological studies at the corresponding arterial sites. The beneficial effect was also observed in the left common carotid arteries that delayed-fasudil treatment reduced the plaque size in a dose-dependent manner. The arterial intima-medial thickness (IMT) and maximal flow velocity of both arteries were lower in fasudil-treated group (100 mg/kg/day) in comparison with the control mice. Furthermore, fasudil treatment (100 mg/kg/day) reduced the macrophage accumulation in atherosclerotic lesions. However, fasudil had no effects on blood pressure and plasma lipid concentrations in both studies. In conclusion, our studies showed that blocking Rho kinase reduced both the early development and later progression of atherosclerotic plaques in apoE-KO mice by using a novel micro-ultrasound approach. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:68 / 73
页数:6
相关论文
共 14 条
  • [1] Rho GTPases in cell biology
    Etienne-Manneville, S
    Hall, A
    [J]. NATURE, 2002, 420 (6916) : 629 - 635
  • [2] Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy
    Gan, Li-ming
    Gronros, Julia
    Hagg, Ulrika
    Wikstrom, Johannes
    Theodoropoulos, Catherine
    Friberg, Peter
    Fritsche-Danielson, Regina
    [J]. ATHEROSCLEROSIS, 2007, 190 (02) : 313 - 320
  • [3] Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo - Effect on endothelial NAD(P)H oxidase system
    Higashi, M
    Shimokawa, H
    Hattori, T
    Hiroki, J
    Mukai, Y
    Morikawa, K
    Ichiki, T
    Takahashi, S
    Takeshita, A
    [J]. CIRCULATION RESEARCH, 2003, 93 (08) : 767 - 775
  • [4] Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse - Model characterization and effects of pravastatin treatment
    Johnson, J
    Carson, K
    Williams, H
    Karanam, S
    Newby, A
    Angelini, G
    George, S
    Jackson, C
    [J]. CIRCULATION, 2005, 111 (11) : 1422 - 1430
  • [5] Role of Rho-kinase and p27 in angiotensin II-induced vascular injury
    Kanda, T
    Hayashi, K
    Wakino, S
    Homma, K
    Yoshioka, K
    Hasegawa, K
    Sugano, N
    Tatematsu, S
    Takamatsu, I
    Mitsuhashi, T
    Saruta, T
    [J]. HYPERTENSION, 2005, 45 (04) : 724 - 729
  • [6] Involvement of Rho-kinase in agonists-induced contractions of arteriosclerotic human arteries
    Kandabashi, T
    Shimokawa, H
    Mukai, Y
    Matoba, T
    Kunihiro, I
    Morikawa, K
    Ito, M
    Takahashi, S
    Kaibuchi, K
    Takeshita, A
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (02) : 243 - 248
  • [7] Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice
    Mallat, Z
    Gojova, A
    Sauzeau, V
    Brun, V
    Silvestre, JS
    Esposito, B
    Merval, R
    Groux, H
    Loirand, G
    Tedgui, A
    [J]. CIRCULATION RESEARCH, 2003, 93 (09) : 884 - 888
  • [8] Mukai Yasushi, 2001, FASEB Journal, V15, P1062
  • [9] Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic Event
    Rawlings, Ron
    Nohria, Anju
    Liu, Ping-Yen
    Donnelly, Jason
    Creager, Mark A.
    Ganz, Peter
    Selwyn, Andrew
    Liao, James K.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (04) : 437 - 441
  • [10] Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
    Shiomi, M
    Ito, T
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (04) : 961 - 968